Compare AES Corp (AES) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AES Corp vs Revvity Inc — how do they compare? AES Corp trades at $14.73 (market cap $10.49B), while Revvity Inc trades at $115.22 (market cap $12.91B). The key difference: Revvity Inc is the larger of the two by market cap, and AES Corp pays the higher dividend (4.79%). Which is the better fit depends on your goals.
| AES | RVTY | |
|---|---|---|
Market Cap | $10.49B | $12.91B |
Sector | Utilities | Technology |
52-Week High | $17.28 | $117.75 |
52-Week Low | $12.51 | $82.26 |
Enterprise Value | $40.75B | $15.23B |
Dividend Yield | 4.79% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AES trades at $14.73, unchanged on the day, with a bullish technical signal from moving averages and a pending acquisition by Global Infrastructure Partners and EQT at $15 per share. The company reported revenue of $12.23B in 2025, with a net income margin of 7.43%, and has beaten earnings estimates in two of the last three quarters. Valuation ratios appear attractive with a P/E of 5.51 and P/S of 0.81, while cash flow from operations improved to $4.31B in 2025.
The outlook is dominated by the acquisition, offering a capped upside to $15. Strong profitability metrics like a 45.05% ROE and a 4.8% dividend yield provide support, but risks include shareholder litigation and regulatory scrutiny over the deal. Analyst sentiment is mixed with 42.86% buy ratings, reflecting uncertainty until transaction closure.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AES Corp
AES is a global power company operating across 14 countries and 4 continents. Its current generation portfolio as of year-end 2021 consists of over 31 gigawatts of generation, with the generation mix composed of renewables (43%), gas (32%), coal (23%), and oil (2%). The company has 3.5 gigawatts of generation under construction. AES has majority ownership and operates six electric utilities distributing power to 2.6 million customers.
Read more on AES →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
